Auris Medical Holding AG (NASDAQ:EARS)’s share price shot up 2.4% during trading on Friday . The company traded as high as $0.95 and last traded at $0.93. 311,812 shares were traded during trading, a decline of 23% from the average session volume of 406,143 shares. The stock had previously closed at $0.95.

Several equities research analysts have recently weighed in on EARS shares. Zacks Investment Research upgraded Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Wednesday, August 30th. Roth Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of Auris Medical Holding AG in a research report on Saturday, July 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Auris Medical Holding AG currently has an average rating of “Hold” and an average target price of $3.25.

The company has a 50-day moving average of $0.73 and a 200 day moving average of $0.75. The stock’s market capitalization is $41.67 million.

Auris Medical Holding AG (NASDAQ:EARS) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.09. Equities research analysts expect that Auris Medical Holding AG will post ($0.63) earnings per share for the current year.

Institutional investors have recently made changes to their positions in the business. Virtu KCG Holdings LLC bought a new stake in shares of Auris Medical Holding AG during the 2nd quarter valued at about $101,000. Sabby Management LLC bought a new stake in Auris Medical Holding AG during the first quarter worth about $133,000. Perceptive Advisors LLC bought a new stake in Auris Medical Holding AG during the first quarter worth about $368,000. Finally, UBS Oconnor LLC bought a new stake in Auris Medical Holding AG during the first quarter worth about $909,000. 28.38% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Auris Medical Holding AG (EARS) Stock Price Up -2.4%” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/08/auris-medical-holding-ag-ears-stock-price-up-2-4.html.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.